SGN-B6A
SGN-B6A is an ADC, which targets integrin beta-6 (ITGB6) through human IgG1 monoclonal antibody Sigvotatug , and exhibits cytotoxicity against multiple integrin beta-6-positive cancer cell through mitotic inhibitor MMAE (HY-15162).
Product Specifications
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; Integrin
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sgn-b6a.html
Purity
99.68
Smiles
[SGN-B6A]
Molecular Weight
150000 (average)
References & Citations
[1]Lyon RP, et al., SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications. Mol Cancer Ther. 2023 Dec 1;22 (12) :1444-1453.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
